TY - JOUR
T1 - The secret ally
T2 - Immunostimulation by anticancer drugs
AU - Galluzzi, Lorenzo
AU - Senovilla, Laura
AU - Zitvogel, Laurence
AU - Kroemer, Guido
N1 - Funding Information:
The authors are supported by grants from the Ligue contre le Cancer (the French National League against Cancer), the AXA Chair for Longevity Research, Cancéropôle Ile-de-France, Institut National du Cancer (the French National Cancer Institute), the Bettencourt-Schueller Foundation, The Fondation de France, the Fondation pour la Recherche Médicale (the Foundation for Medical Research), the Agence National de la Recherche (the National Agency for Research) and the European Commission (APO-SYS, ArtForce, ChemoRes. Death-Train) as well as the LabEx Immuno-Oncology.
PY - 2012/3/1
Y1 - 2012/3/1
N2 - It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents g- including classical chemotherapeutics and targeted compounds g- stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.
AB - It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents g- including classical chemotherapeutics and targeted compounds g- stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.
UR - http://www.scopus.com/inward/record.url?scp=84857789296&partnerID=8YFLogxK
U2 - 10.1038/nrd3626
DO - 10.1038/nrd3626
M3 - Review article
C2 - 22301798
AN - SCOPUS:84857789296
SN - 1474-1776
VL - 11
SP - 215
EP - 233
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 3
ER -